Why Canopy Growth (TSX:WEED) Is the 1 Weed Stock That Won’t Run Out of Business

The Canopy Growth stock is worth watching after the company reported significant progress during its Q3 fiscal 2020. Over the next 90 days, management will be rightsizing the business and building credibility with all stakeholders.

| More on:
edit Jars of marijuana

Image source: Getty Images

The cannabis industry had a turbulent 2019, and the majority of the players were not reporting profits. This year, however, you might see only one genuinely competent and strong participant to operate and not run out of business. Canopy Growth (TSX:WEED)(NYSE:CGC), the sector’s bellwether, is back in the saddle.

But is Canopy Growth sure to turn the corner in 2020? The recent earnings surprise indicates that it was able to stop the bleeding. Now, the company has a crack at finally achieving profitability.

Business growth opportunities of a lifetime

New CEO David Klein kicked off the earnings call last February 14, 2020. His said his reason for joining Canopy Growth was because the cannabis market is one of the most exciting business growth opportunities of our lifetime.

The fiscal 2020 third-quarter results were not spectacular, although the company made significant progress. Canopy’s CFO Mike Lee gave the financial highlights, beginning with the 13% growth in total net revenue. Its business was able to generate 34% gross margins before fair-value impacts.

Canopy had a loss of $92 million, which is better than the $156 million loss in the previous quarter. Canada’s recreational marijuana posted a 10% increase due to balanced growth in the company’s B2B and B2C channels. Medical sales saw a 5% quarter-over-quarter increase, including a 3% increase in international medical.

The strategic acquisitions (Storz & Bickel, This Works, and BioSteel) contributed almost 22% to total revenue. Mr. Lee said Canopy Growth will still be facing some headwinds. Management, however, is designing a supply chain and footprint that applies to the market realities today and well into the next couple of years.

Cash rich

Klein admits the road ahead is not going to be an easy one. His topmost priorities are the following: improve Canopy’s connection with consumers, bring more focus and discipline to the organization, and define a very visible path to profitability and positive cash flow.

Being a subordinate company of Constellation Brands is the advantage of Canopy Growth. The new CEO is assuring investors that the company will not run of cash. Also, the way to win in the market is to possess the most-trusted and most-loved brands.

With an industry that is evolving, Canopy sees the need to focus on specific markets and product lines where the company has the legitimate right to win. Another asset waiting to deliver is the vaunted line of beverage products. Canopy’s weed drinks have yet to finish scaling production. Drinkable products are the next big thing.

Beacon of hope

According to Canopy Growth’s new CEO, there is a lot of work to be done. The company is taking steps to reduce costs and right-size the business to produce a healthy margin profile and generate cash in the years ahead.

Canopy is hoping the days of burning cash and disappointing sales are over. David Klein is confident that Canopy can capitalize on the opportunity to create an unassailable global position in cannabis. Analysts are forecasting the price of $26.40 today could soar by 127.27% to $60 in the next 12 months. Keep your fingers crossed.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Constellation Brands.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »